Skip to content
★ Sign in to follow
프로티나 logo

프로티나 Stock: price and insider trades · South Korea

KR·Mcap ₩594BHealth Care

No insider purchase over the last 90 days. The latest, by 안정현, was filed 30 Apr 2026.

프로티나: what insiders have been doing

Every trade that managers of 프로티나 disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. Over the twelve months to 2 November 2026, 20 filings were filed, from 11 insiders.

Both sides are active: 17 purchases worth €619k and 1 sale, from 10 insiders and 1 insider respectively. No amount is published for 9 filings, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a purchase of €391k from 윤태영, disclosed on 30 April 2026, or 0.17% of market capitalisation. Among those who bought: 7 board members and 2 senior executives.

For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 20 filings here. Looking back to 2025, when coverage begins, insiders filed 27 purchases and 4 sales.

Within a 30-day window, 9 purchases overlapped with buying by a second insider. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last insider purchase was made public on 30 April 2026, 193 days ago. Between a trade and the moment it shows up on DART (FSS), the median delay is 3 days. That lag is the time during which only the insider knows about the trade.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.

Insider Decl.
33
Thresholds
n/a
Buy Volume
€92M
27 ops. · all time
Sell Volume
€8M
4 ops. · all time

Who traded when

BuySale
Lb인베스트먼트2 buys2 sales
윤태영3 buys
이대승3 buys
이홍원3 buys
정소이2 buys1 sale
Park Kyung Chan2 buys

+8 other insiders

Since the insiders bought

  • Filed 30 Apr 2026 · 193 days ago · €17k
    -1.6%
    Entry ₩55,200 · Close 30 Oct 2026 ₩54,300
  • Filed 30 Apr 2026 · 193 days ago · €3,025
    -1.6%
    Entry ₩55,200 · Close 30 Oct 2026 ₩54,300
  • Filed 30 Apr 2026 · 193 days ago · €17k
    -1.6%
    Entry ₩55,200 · Close 30 Oct 2026 ₩54,300

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩54,300
Analyst consensus
·
Income statement
Revenue₩3B
Gross profit₩1.5B52% margin
EBITDA-₩7.6B-259% margin
Net income-₩9B-305.4% margin
Balance sheet & cash
Market cap₩594B
Total debt₩866.6M
Free Cash Flow-₩9.6B
Profitability & ownership
% insiders23.4%
% institutions13.2%
Last declaration on 30 April 2026
Declarations40 total
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • ▲
    이사Executives
    29M KRW33DART
    3,400 shares@ ₩8,477.000.0072% mcap100.0% of flowShareKRXDART:20260430001836
    Canonical exit: 26 Jul 2026 (T+90)
  • ▲
    이사Executives
    5M KRW33DART
    719 shares@ ₩7,280.000.0013% mcap100.0% of flowShareKRXDART:20260430001847
    Canonical exit: 26 Jul 2026 (T+90)
  • ▲
    이사Executives
    29M KRW33DART
    3,518 shares@ ₩8,357.91250.0074% mcap100.0% of flowShareKRXDART:20260430001865
    Canonical exit: 26 Jul 2026 (T+90)
  • ▲
    Executives
    €391k28DART
    12,000 shares0.17% mcap100.0% of flowKRXDART:20260430001810
    Canonical exit: 26 Jul 2026 (T+90)
  • ▲
    이사Executives
    25M KRW33DART
    3,000 shares@ ₩8,477.000.0064% mcap100.0% of flowShareKRXDART:20260430001878
    Canonical exit: 26 Jul 2026 (T+90)
  • ▲
    이사Executives
    7M KRW33DART
    1,800 shares@ ₩4,158.000.0019% mcap100.0% of flowShareKRXDART:20260430001841
    Canonical exit: 26 Jul 2026 (T+90)
  • ▲
    이사Executives
    13M KRW33DART
    3,343 shares@ ₩3,780.000.0032% mcap100.0% of flowShareKRXDART:20260430001829
    Canonical exit: 26 Jul 2026 (T+90)
  • ▲
    상무Executives
    257M KRW37DART
    68,000 shares@ ₩3,780.000.065% mcap100.0% of flowShareKRXDART:20260430001824
    Canonical exit: 26 Jul 2026 (T+90)
  • ▲
    상무Executives
    28M KRW37DART
    3,368 shares@ ₩8,220.52730.0069% mcap100.0% of flowShareKRXDART:20260430001816
    Canonical exit: 26 Jul 2026 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ▼
    이사Executives(filed)
    €196kest.0DART
    3,000 sharesShareKRXDART:20251230000619
  • ▲
    이사Executives(filed)
    €89kest.0DART
    2,000 sharesShareKRXDART:20251127001285
    Canonical exit: 25 Feb 2026 (T+90)
  • ●
    Executives
    Executives
    0DART
  • ▲
    이사Executives(filed)
    €140kest.0DART
    3,133 sharesShareKRXDART:20251127001241
    Canonical exit: 25 Feb 2026 (T+90)
  • ▲
    이사Executives(filed)
    €148kest.0DART
    3,315 sharesShareKRXDART:20251127001253
    Canonical exit: 25 Feb 2026 (T+90)
  • ▲
    이사Executives(filed)
    €148kest.0DART
    3,315 sharesShareKRXDART:20251127001299
    Canonical exit: 25 Feb 2026 (T+90)
  • ▲
    상무Executives(filed)
    €140kest.0DART
    3,133 sharesShareKRXDART:20251127001233
    Canonical exit: 25 Feb 2026 (T+90)
  • ▲
    이사Executives(filed)
    €151kest.0DART
    3,382 sharesShareKRXDART:20251127001260
    Canonical exit: 25 Feb 2026 (T+90)

25 of 40 declarations

About 프로티나

Protinah is a company operating in the health and pharmaceutical sector, listed on the XKRX. It specializes in the development of innovative pharmaceutical products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations